Maya Khalil, MD

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Maya Khalil, MD, discusses key clinical trial updates on the use of nivolumab and ipilimumab with or without chemotherapy in non–small cell lung cancer.